Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells

Molecular Oncology

Volumn 8, Issue 7, 2014, Pages 1181-1195

  Brizuela, Leyre ^a,b,c   Martin, Claire ^a,b,c   Jeannot, Pauline ^a,b,c   Ader, Isabelle ^a,b,c   Gstalder, Cécile ^a,b,c   Andrieu, Guillaume ^a,b,c   Bocquet, Magalie ^a,b,c   Laffosse, Jean Michel ^b,d   Gomez Brouchet, Anne ^b,d   Malavaud, Bernard ^a,b,c,d   Sabbadini, Roger A ^e   Cuvillier, Olivier ^a,b,c  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Equipe Labellisée Ligue Nationale Contre le Cancer LNCC   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e Lpath Inc   (United States)

Author keywords

Differentiation; Docetaxel; Osteoblasts; Radiotherapy; Sphingomab; Sphingosine kinase

Indexed keywords

G PROTEIN COUPLED RECEPTOR; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TRANSCRIPTION FACTOR RUNX2; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; BONE NEOPLASMS; CELL LINE; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MICE; OSTEOBLASTS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84908504987     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.04.001     Document Type: Article

References (57)

1. Bakker A.D., Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. Methods Mol. Biol. 2012, 816:19-29.
2. Barth B.M., Shanmugavelandy S.S., Kaiser J.M., McGovern C., Altinoglu E.I., Haakenson J.K., Hengst J.A., Gilius E.L., Knupp S.A., Fox T.E., Smith J.P., Ritty T.M., Adair J.H., Kester M. PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate. ACS Nano 2013, 7:2132-2144.
3. Blaszczyk N., Masri B.A., Mawji N.R., Ueda T., McAlinden G., Duncan C.P., Bruchovsky N., Schweikert H.U., Schnabel D., Jones E.C., Sadar M.D. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin. Cancer Res. 2004, 10:1860-1869.
4. Brizuela L., Ader I., Mazerolles C., Bocquet M., Malavaud B., Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol. Cancer Ther. 2012, 11:1841-1851.
5. Brizuela L., Cuvillier O. Biochemical methods for quantifying sphingolipids: ceramide, sphingosine, sphingosine kinase-1 activity, and sphingosine-1-phosphate. Methods Mol. Biol. 2012, 874:1-20.
6. Brizuela L., Dayon A., Doumerc N., Ader I., Golzio M., Izard J.C., Hara Y., Malavaud B., Cuvillier O. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 2010, 24:3882-3894.
7. Charhon S.A., Chapuy M.C., Delvin E.E., Valentin-Opran A., Edouard C.M., Meunier P.J. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983, 51:918-924.
8. Cuvillier O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta 2002, 1585:153-162.
9. Cuvillier O. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin. Ther. Targets 2008, 12:1009-1020.
10. Cuvillier O., Mayhew E., Janoff A.S., Spiegel S. Liposomal ET-18-OCH(3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood 1999, 94:3583-3592.
11. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
12. Dayon A., Brizuela L., Martin C., Mazerolles C., Pirot N., Doumerc N., Nogueira L., Golzio M., Teissié J., Serre G., Rischmann P., Malavaud B., Cuvillier O. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One 2009, 4:e8048.
13. Festuccia C., Bologna M., Gravina G.L., Guerra F., Angelucci A., Villanova I., Millimaggi D., Teti A. Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int. J. Cancer 1999, 81:395-403.
14. French K.J., Schrecengost R.S., Lee B.D., Zhuang Y., Smith S.N., Eberly J.L., Yun J.K., Smith C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63:5962-5969.
15. Fukuhara S., Simmons S., Kawamura S., Inoue A., Orba Y., Tokudome T., Sunden Y., Arai Y., Moriwaki K., Ishida J., Uemura A., Kiyonari H., Abe T., Fukamizu A., Hirashima M., Sawa H., Aoki J., Ishii M., Mochizuki N. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J.Clin. Invest 2012, 122:1416-1426.
16. Gleave M., Hsieh J.T., Gao C.A., von Eschenbach A.C., Chung L.W. Acceleration of human prostate cancer growth invivo by factors produced by prostate and bone fibroblasts. Cancer Res. 1991, 51:3753-3761.
17. Gomez-Brouchet A., Pchejetski D., Brizuela L., Garcia V., Altie M.F., Maddelein M.L., Delisle M.B., Cuvillier O. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol. Pharmacol. 2007, 72:341-349.
18. Hisano Y., Kobayashi N., Kawahara A., Yamaguchi A., Nishi T. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J.Biol. Chem. 2011, 286:1758-1766.
19. Ishii M., Egen J.G., Klauschen F., Meier-Schellersheim M., Saeki Y., Vacher J., Proia R.L., Germain R.N. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528.
20. Ishii M., Kikuta J., Shimazu Y., Meier-Schellersheim M., Germain R.N. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling invivo. J.Exp. Med. 2010, 207:2793-2798.
21. Jacobs S.C. Spread of prostatic cancer to bone. Urology 1983, 21:337-344.
22. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
23. Kawahara A., Nishi T., Hisano Y., Fukui H., Yamaguchi A., Mochizuki N. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 2009, 323:524-527.
24. Lang S.H., Miller W.R., Habib F.K. Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. Prostate 1995, 27:287-293.
25. Lin D.L., Tarnowski C.P., Zhang J., Dai J., Rohn E., Patel A.H., Morris M.D., Keller E.T. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes invitro. Prostate 2001, 47:212-221.
26. Logothetis C.J., Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 2005, 5:21-28.
27. Lu Y., Zhang J., Dai J., Dehne L.A., Mizokami A., Yao Z., Keller E.T. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin. Exp. Metastasis 2004, 21:399-408.
28. Maceyka M., Harikumar K.B., Milstien S., Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012, 22:50-60.
29. Malavaud B., Pchejetski D., Mazerolles C., de Paiva G.R., Calvet C., Doumerc N., Pitson S., Rischmann P., Cuvillier O. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur. J. Cancer 2010, 46:3417-3424.
30. Martin C., Lafosse J.M., Malavaud B., Cuvillier O. Sphingosine kinase-1 mediates androgen-induced osteoblast cell growth. Biochem. Biophys. Res. Commun. 2010, 391:669-673.
31. Mendelson K., Evans T., Hla T. Sphingosine 1-phosphate signalling. Development 2014, 141:5-9.
32. Millimaggi D., Festuccia C., Angelucci A., D'Ascenzo S., Rucci N., Flati S., Bologna M., Teti A., Pavan A., Dolo V. Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int. J. Oncol. 2006, 28:909-914.
33. Nagahashi M., Kim E.Y., Yamada A., Ramachandran S., Allegood J.C., Hait N.C., Maceyka M., Milstien S., Takabe K., Spiegel S. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J. 2013, 27:1001-1011.
34. Nava V.E., Cuvillier O., Edsall L.C., Kimura K., Milstien S., Gelmann E.P., Spiegel S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res. 2000, 60:4468-4474.
35. O'Brien N., Jones S.T., Williams D.G., Cunningham H.B., Moreno K., Visentin B., Gentile A., Vekich J., Shestowsky W., Hiraiwa M., Matteo R., Cavalli A., Grotjahn D., Grant M., Hansen G., Campbell M.A., Sabbadini R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J.Lipid Res. 2009, 50:2245-2257.
36. Olivera A., Kohama T., Edsall L., Nava V., Cuvillier O., Poulton S., Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J.Cell Biol. 1999, 147:545-558.
37. Pchejetski D., Boehler T., Brizuela L., Sauer L., Doumerc N., Golzio M., Salunkhe V., Teissie J., Malavaud B., Waxman J., Cuvillier O. FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010, 70:8651-8661.
38. Pchejetski D., Doumerc N., Golzio M., Naymark M., Teissie J., Kohama T., Waxman J., Malavaud B., Cuvillier O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther. 2008, 7:1836-1845.
39. Pchejetski D., Golzio M., Bonhoure E., Calvet C., Doumerc N., Garcia V., Mazerolles C., Rischmann P., Teissie J., Malavaud B., Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005, 65:11667-11675.
40. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. U S A 2008, 105:20764-20769.
41. Pitson S.M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. 2011, 36:97-107.
42. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., Wattenberg B.W. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003, 22:5491-5500.
43. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 2010, 10:489-503.
44. Quarles L.D., Yohay D.A., Lever L.W., Caton R., Wenstrup R.J. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an invitro model of osteoblast development. J.Bone Miner Res. 1992, 7:683-692.
45. Rex K., Jeffries S., Brown M.L., Carlson T., Coxon A., Fajardo F., Frank B., Gustin D., Kamb A., Kassner P.D., Li S., Li Y., Morgenstern K., Plant M., Quon K., Ruefli-Brasse A., Schmidt J., Swearingen E., Walker N., Wang Z., Watson J.E., Wickramasinghe D., Wong M., Xu G., Wesche H. Sphingosine kinase activity is not required for tumor cell viability. PLoS One 2013, 8:e68328.
46. Ritchie C.K., Andrews L.R., Thomas K.G., Tindall D.J., Fitzpatrick L.A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997, 138:1145-1150.
47. Rosen H., Gonzalez-Cabrera P.J., Sanna M.G., Brown S. Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 2009, 78:743-768.
48. Ryu J., Kim H.J., Chang E.J., Huang H., Banno Y., Kim H.H. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 2006, 25:5840-5851.
49. Sabbadini R.A. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br. J. Pharmacol. 2011, 162:1225-1238.
50. Sauer L., Nunes J., Salunkhe V., Skalska L., Kohama T., Cuvillier O., Waxman J., Pchejetski D. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int. J. Cancer 2009, 125:2728-2736.
51. Schnute M.E., McReynolds M.D., Kasten T., Yates M., Jerome G., Rains J.W., Hall T., Chrencik J., Kraus M., Cronin C.N., Saabye M., Highkin M.K., Broadus R., Ogawa S., Cukyne K., Zawadzke L.E., Peterkin V., Iyanar K., Scholten J.A., Wendling J., Fujiwara H., Nemirovskiy O., Wittwer A.J., Nagiec M.M. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem. J. 2012, 444:79-88.
52. Sturge J., Caley M.P., Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 2011, 8:357-368.
53. Visentin B., Vekich J.A., Sibbald B.J., Cavalli A.L., Moreno K.M., Matteo R.G., Garland W.A., Lu Y., Yu S., Hall H.S., Kundra V., Mills G.B., Sabbadini R.A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006, 9:225-238.
54. Wang G., Haile S., Comuzzi B., Tien A.H., Wang J., Yong T.M., Jelescu-Bodos A.E., Blaszczyk N., Vessella R.L., Masri B.A., Sadar M.D. Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Res. 2009, 69:3433-3442.
55. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11:411-425.
56. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., Hu M., Olive M., Martinez L.A., Wood C.G., Logothetis C.J., Karsenty G., Navone N.M. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001, 61:5652-5659.
57. Zunich S.M., Douglas T., Valdovinos M., Chang T., Bushman W., Walterhouse D., Iannaccone P., Lamm M.L. Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation. Mol. Cancer 2009, 8:12.